PURAVANKARA®

PURAVANKARA LIMITED

Registered Office: No.130/1, Ulsoor Road, Bengaluru-560 042, India
Corporate Identification Number: L45200KA1986PLC051571
Email: investors@puravankara.com
Tel: +91-80-43439999 | Fax: +91-80-2559 9350

Extract of standalone and consolidated unaudited financial results for the quarter ended 30 June 2018

(₹/Crores, except share and per share data)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended 30.06.2018 [Unaudited]	Preceding Quarter ended 31-03.2018 [Audited]	Corresponding Quarter ended 30.06.2017 [Unaudited]	Previous Year ended 31.03.2018 [Audited]	Quarter ended 30.06.2018 [Unaudited]	Preceding Quarter ended 31-03.2018 [Audited]	Corresponding Quarter ended 30.06.2017 [Unaudited]	Previous Year ended 31.03.2018 [Audited]
1.	Total income from operations	269.43	175.90	214.66	885.60	382.02	287.95	338.49	1,414.90
2.	Net profit/(loss) for the period (before Tax, Exceptional and/or Extraordinary items)	26.38	23.46	11.17	86.99	35.47	27.79	31.88	131.23
3.	Net profit/(loss) for the period before tax (after Exceptional and/or Extraordinary items)	26.38	23.46	11.17	86.99	35.47	27.79	31.88	131.23
4.	Net Profit/(loss) for the period after tax (after Exceptional and/or Extraordinary items)	21.63	23.46	7.10	77.23	26.85	24.55	20.07	91.40
5.	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)	21.22	23.69	7.13	76.76	26.46	24.88	20.05	91.16
6.	Equity Share Capital (face value ˙ 5/share)	118.58	118.58	118.58	118.58	118.58	118.58	118.58	118.58
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	1,874.10	-	-	-	2,274.59
8.	Earnings per share (before extraordinary items) (nominal value ₹ 5 per share)								
	Basic: (₹)	0.91	0.99	0.30	3.26	1.13	1.04	0.85	3.85
	Diluted: (₹)	0.91	0.99	0.30	3.26	1.13	1.04	0.85	3.85

Notes:

1 The above consolidated financial results of Puravankara Limited ('the Company') have been reviewed by the Audit Committee and taken on record at the meeting of the Board of Directors of the Company held on 10.08.2018.The statutory auditors of the Company have carried out a limited review on the above consolidated financial results of the Company.

2 The Group's business activity falls within a single reportable segment, i.e., real estate development. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment. Further, the Group is domiciled in India and does not have significant foreign operations.

3 Ind AS 115 Revenue from Contracts with Customers and amendments to Ind AS 40 Investment Property consequent to issuance of Ind AS 115, mandatory for reporting periods beginning on or after April 1, 2018, replaces existing requirements of recognition of revenue and derecognition of investment property. The application of Ind AS 115 and Amendments to Ind AS 40 have impacted the Group's accounting for revenue from real estate projects and gain/loss arising from derecognition of investment property.

The Group has applied the modified retrospective approach to all contracts as of April 1, 2018 and has given impact of application of Ind AS 115 and amendments to Ind AS 40 by debit to retained earnings as at the said date by Rs. 610 crores (net of tax). Accordingly, the comparatives have not been restated and hence not comparable with previous period figures. Due to the application of Ind AS 115 and amendments to Ind AS 40 for the quarter ended June 30, 2018, revenue from operations is higher by Rs. 191 crores (including gain on sale of investment property of Rs. 27 crores) and net profit after tax (before non controlling interests) is higher by Rs.78 crores. The basic and diluted EPS for the period is Rs.1.13 per share, instead of loss per share of Rs. 2.18 per share.

4 The Board of Directors of the Company at their meeting held on August 10, 2018 have recommended a final dividend of Rs.1.60 per equity share of Rs. 5 each for the financial year ended March 31, 2018. The said proposed dividend are subject to approval at the ensuing annual general meeting and are not recognised as a liability (including dividend distribution tax thereon) as at 30.06.2018.

5 The above is an extract of the detailed format of quarter ended financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarter ended financial results are available on the website of Stock Exchanges at 'www.bseindia.com' and 'www.nseindia.com' and on the company's website at 'www.puravankara.com'.

For and on behalf of the Board of Directors of
Puravankara Limited

Nani R Choksey
Joint Managing Director
DIN 00504555

Bengaluru
10 August 2018

RattanIndia Power Limited

(Formerly known as Indiabulls Power Limited.)

Extract from the Unaudited Financial Results of RattanIndia Power Limited (Formerly Known as Indiabulls Power Limited.) for the Quarter ended 30 June 2018

(Rs. In Crore)

Sr. No	Particulars	Quarter Ended			Year Ended
		30.06.2018 (Unaudited)	31.03.2018 (Audited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1.	Total income from operations	690.72	654.92	482.21	2,015.38
2.	Net Profit/ (Loss) for the period (before tax, exceptional and/or extraordinary items)	(7.60)	2.93	(136.96)	(411.47)
3.	Net Profit/ (Loss) for the period before tax (after exceptional and/or extraordinary items)	(7.60)	2.93	(136.96)	(411.47)
4.	Net Profit/ (Loss) for the period after tax (after exceptional and/or extraordinary items)	(7.60)	(3.98)	(136.96)	(418.38)
5.	Total comprehensive income/(loss) for the period [comprising profit/(loss) for the period after tax and other comprehensive income (net of tax)]	(7.54)	(3.95)	(137.01)	(418.14)
6.	Paid-up equity share capital (Face Value of Rs. 10 per Equity Share)	2,952.93	2,952.93	2,952.93	2,952.93
7.	Other Equity (excluding revaluation reserve) as shown in the balance sheet of previous year				1,654.44
8.	Earnings Per Share (Face Value of Rs. 10 per Equity Share) (for continuing and discontinued operations)				
	- Basic (Rs.)	(0.03)*	(0.01)*	(0.46)*	(1.42)
	- Diluted (Rs.)	(0.03)*	(0.01)*	(0.46)*	(1.42)
	*(EPS for the quarter are not annualised)				

Notes:

(a) The above is an extract of the detailed format of Financial Results of the quarter ended 30 June 2018 filed with the stock exchanges under Regulation 33 of the SEBI (Listing and other Disclosure requirements) Regulations, 2015. The full format of the unaudited financial results are available on the Company's website at www.rattanindia.com and the Stock Exchange websites at www.bseindia.com and www.nseindia.com.

(b) The Auditors in their Limited Review Report on the standalone financial statement for the quarter ended 30 June 2018 have brought out that:

(i) The Company has a non-current investment of Rs. 3,026.26 crore in, inter corporate deposits (classified under current assets) of Rs. 48.48 crore and trade receivable of Rs. 5.33 crore recoverable from RattanIndia Nasik Power Limited, a wholly-owned subsidiary of the Company, as at 30 June 2018. The subsidiary company has incurred losses since its inception and is yet to commence operations. The accumulated losses in the subsidiary company amount to Rs. 1,965.43 crore as at 31 March 2018, and the management of the subsidiary company had determined that a material uncertainty exists, as at 31 March 2018, that may cast significant doubt about the subsidiary company's ability to continue as a going concern. However, in the absence of any impairment assessment performed by the management, we are unable to obtain sufficient appropriate evidence to comment on any adjustment that may be required to be made to the carrying values of the above mentioned non-current investment, inter corporate deposits and trade receivables as at 30 June 2018, and the consequential impact on the accompanying standalone financial results.

(ii) The Company has a non-current investment of Rs. 432.77 crore in and inter corporate deposits (classified as loans under non-current assets) of Rs. 122.58 crore recoverable from Bracond Limited, a wholly-owned subsidiary of the Company, as at 30 June 2018. In the absence of any impairment assessment performed by the management, we are unable to obtain sufficient appropriate evidence to comment on any adjustment that may be required to be made to the carrying values of the above mentioned non-current investment and inter corporate deposits as at 31 March 2018, and the consequential impact on the accompanying standalone financial results.

Registered Office : 5th Floor, Tower-B, Worldmark 1, Aerocity, New Delhi - 110037
CIN: L40102DL2007PLC169082

Place : New Delhi
Date : 10 August, 2018

On behalf of the Board of Directors
For RattanIndia Power Limited

Jayant Kawale
Managing Director

UTTAR HARYANA BIJLI VITRAN NIGAM

Office of The Chief Engineer/MM, Shakti Bhawan, Sector 6, Panchkula.
Tel.: 2561931-39, 2560438 Fax: 0172-2566404
Regd. & Corp. Offices C-16 Vidyut Sadan Sector 6, Panchkula Haryana
Ph. No. 0172-3019133 Fax: 0172-3019119
Web Site: www.uhbvn.com
CIN No. U40109HR1999SGC034166
E-mail: cgmmmuhbvn@gmail.com

NOTICE INVITING TENDERS

(only through e-procurement)

NOTICE INVITED TENDER No. 221/UH/MM/XEN/P-IV/MM/QH-II/1982

DATED: 06.08.2018

Offers are invited for procurement of following material on FIRM Price & 'FOR' destination basis anywhere in Haryana by fixing the annual rate contract as per details given below:-

Description of item	Total Qty. (In Nos.)	Estimated cost (In Rs.)
11 KV 5 KN Polymer Type Pin Insulator along with Pin as per Nigam Technical Specification no. 84. SE/R-I/P&D/Xen-DD-II	**UHBVN** Min.=52000 Max=78000 **DHBVN** Min.=140000 Max=210000 **TOTAL** Min.= 192000 Max= 288000	2.99 crore **(As per Min qty.)**

Date of start	Last date of submission	Opening date of part-I
09.08.2018 at 10.00 Hrs	03.09.2018 at 13.00 Hrs	03.09.2018 at 15.00 Hrs

Tender documents having detailed terms and conditions can be seen/downloaded from the portal https:// haryanaeprocurement.gov.in and www.uhbvn.org.in/web/portal/tenders

Superintending Engineer/P-II (MM)
UHBVN, Panchkula

70053/HRY

NOTICE INVITING E-TENDER

e-Tender No. 11 of 2018-2019 of EE/BD/PHED, vide Memo bearing No. 1382/BD Dated 10.08.2018

e-Tender is hereby invited on behalf of the Governor of West Bengal, vide e-Tender No. WBPHED/EE/BD/NIET_11 of 2018-2019 (Tender ID : 2018_PHED_185959_1 to 4) in Connection with "Sinking of Ground Bored Tube Well in different Block, under Dakshin Dinajpur District" for details please see website : **https://etender.wb.nic.in**. Online Bid Submission Start and end date 11.08.2018 at 10.00 A.M. and 27.08.2018 upto 02.00 P.M. respectively.

Sd/-
Executive Engineer
Balurghat Division, PHED

J. TAPARIA PROJECTS LIMITED

CIN : L74210WB1980PLC032979
Regd. Office : 3, SYNAGOUGE STREET, KOLKATA - 700 001
Telephone : 033 2230 5244, E-mail : info@jtapariaprojects.com,
Wetsite : www.jtapariaprojects.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018. (Rs. in Lakhs)

Particulars	STANDALONE			
	Quarter ended June 30, 2018 (Unaudited)	Quarter ended March 31, 2018 (Audited)	Quarter ended June 30, 2017 (Unaudited)	Year ended March 31, 2018 (Audited)
Total income from operations (net)	0.036	1.266	0.180	1.792
Net Profit / (Loss) from ordinary activities after tax	-6.244	-1.643	-5.678	-10.383
Net Profit / (Loss) for the period after tax (after Extraordinary items)	-6.240	-1.643	-5.678	-10.383
Equity Share Capital	1620.000	1620.000	1620.000	1620.000
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of Previous year)	0.000	0.000	0.000	172.973
Earnings Per Share (before extraordinary items) (of Rs. 10/- each)				
Basic :	-0.039	-0.010	-0.035	-0.064
Diluted :	-0.039	-0.010	-0.035	-0.064
Earnings Per Share (after extraordinary items) (of Rs. 10/- each)				
Basic :	-0.039	-0.010	-0.035	-0.064
Diluted :	-0.039	-0.010	-0.035	-0.064

Note :
The above is an extract of the detailed format of Financial Results for the Quarter ended 30.06.2018 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter ended 30.06.2018 is available on the Stock Exchange websites.
Company's website : http://jtapariaprojects.com/financial-result.php
BSE Limited : www.bseindia.com

Notes :
1) The said financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held on 10th August 2018.
2) In accordance with the requirements under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Statutory Auditors have performed a limited review of the financial results of J. Taparia Projects Limited for the quarter ended 30th June 2018. There are no qualifications in the limited review report issued for the said period.

For and on behalf of the Board of
J. Taparia Projects Limited
SD/-
Sanjit Dhawa
DIN : 05162937
Managing Director

Place : Kolkata
Date : 10th August, 2018.

glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.
Tel: 91 22 4018 9999 **Fax:** 91 22 4018 9986 **Email:** complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of Unaudited Financial Results for the quarter ended 30th June, 2018

(₹ in Millions)

Sr. No.	Particulars (Refer notes below)	Standalone (Ind AS)				Consolidated (Ind AS)				Consolidated (IFRS)			
		Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10)	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-2018 (Audited)	Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10)	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-2018 (Audited)	Quarter ended 30-06-2018 (Unaudited)	Quarter ended 31-03-2018 (Audited) (Refer note 10)	Quarter ended 30-06-2017 (Unaudited)	Year ended 31-03-2018 (Audited)
I	Revenue from operations												
	(a) Net sales	15,632.28	15,063.27	15,109.26	60,960.52	21,293.66	22,478.93	23,293.94	89,722.32	21,293.66	22,478.93	23,293.94	89,722.32
	(b) Other operating income	551.79	1,614.18	368.52	3,358.32	362.51	319.23	336.08	1,308.38	362.51	319.23	336.08	1,308.38
	Total Revenue from operations	16,184.07	16,677.45	15,477.78	64,318.84	21,656.17	22,798.16	23,630.02	91,030.70	21,656.17	22,798.16	23,630.02	91,030.70
II	Other income	1,736.49	442.98	425.88	1,804.22	1,382.16	695.52	152.87	914.00	1,382.16	695.52	152.87	914.00
III	Total income (I + II)	17,920.56	17,120.43	15,903.66	66,123.06	23,038.33	23,493.68	23,782.89	91,944.70	23,038.33	23,493.68	23,782.89	91,944.70
IV	Expenses												
	(a) Cost of materials consumed	5,147.65	5,312.54	5,000.21	20,385.67	4,951.83	6,149.42	4,856.67	21,501.10	4,951.83	6,149.42	4,856.67	21,501.10
	(b) Purchase of stock-in-trade	746.72	632.69	693.06	2,881.77	2,452.52	1,734.00	2,609.16	7,547.45	2,452.52	1,734.00	2,609.16	7,547.45
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(172.13)	347.33	(109.34)	518.47	183.62	(40.39)	(251.37)	1,337.12	183.62	(40.39)	(251.37)	1,337.12
	(d) Employee benefits expense	2,296.89	2,323.30	2,077.68	10,219.21	4,525.09	4,642.73	3,843.96	18,718.41	4,525.09	4,642.73	3,843.96	18,718.41
	(e) Finance costs	551.71	507.22	457.37	1,908.98	790.12	743.88	708.61	2,855.67	790.12	743.88	708.61	2,855.67
	(f) Depreciation and Amortisation expense	334.17	298.18	299.41	1,182.04	793.84	735.32	777.32	3,018.76	944.78	894.24	877.21	3,540.67
	(g) Other expenses	4,061.97	4,758.48	4,286.75	16,838.67	6,074.28	7,044.05	6,797.11	25,772.89	6,074.28	7,046.35	6,797.82	25,776.33
	Total expenses (IV)	12,966.98	14,179.74	12,705.14	53,934.81	19,771.30	21,009.01	19,341.46	80,751.40	19,922.24	21,170.23	19,442.06	81,276.75
V	Profit/(loss) before exceptional items and tax (III-IV)	4,953.58	2,940.69	3,198.52	12,188.25	3,267.03	2,484.67	4,441.43	11,193.30	3,116.09	2,323.45	4,340.83	10,667.95
VI	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
VII	Profit/(loss) before tax (V-VI)	4,953.58	2,940.69	3,198.52	12,188.25	3,267.03	2,484.67	4,441.43	11,193.30	3,116.09	2,323.45	4,340.83	10,667.95
VIII	Tax expense :												
	Current tax	1,070.08	733.52	682.31	2,706.77	1,116.28	961.43	790.13	3,256.90	1,116.28	948.64	790.13	3,244.11
	Deferred tax	(90.41)	(7.95)	(192.17)	(661.99)	(179.15)	6.97	317.49	(102.30)	(227.98)	(135.56)	295.93	(318.99)
IX	Profit/(loss) for the period (VII - VIII)	3,973.91	2,215.12	2,708.38	10,143.47	2,329.90	1,516.27	3,333.81	8,038.70	2,227.79	1,510.37	3,254.77	7,742.83
X	Other comprehensive income												
	A (i) Items that will not be reclassified to profit or loss	25.10	36.41	(8.60)	(10.20)	28.10	9.93	(15.46)	41.96	28.10	9.93	(15.46)	41.96
	(ii)Income tax relating to items that will not be reclassified to profit or loss	(8.77)	(12.60)	2.98	3.53	(9.16)	(9.15)	3.98	(3.25)	(9.16)	(9.15)	3.98	(3.25)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	(2,725.02)	(511.28)	(354.51)	(778.78)	(2,753.50)	(463.92)	(350.19)	(696.17)
	(ii)Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
XI	Total comprehensive income	3,990.24	2,238.93	2,702.76	10,136.80	(376.18)	1,005.77	2,967.82	7,298.63	(506.77)	1,047.23	2,893.10	7,085.37
XII	Total comprehensive income attributable to:												
	- Non-controlling interests	-	-	-	-	(0.04)	0.47	0.13	0.92	(0.04)	0.47	0.13	0.92
	- Owners of the Company	3,990.24	2,238.93	2,702.76	10,136.80	(376.14)	1,005.30	2,967.69	7,297.71	(506.73)	1,046.76	2,892.97	7,084.45
XIII	Other equity	-	-	-	1,03,632.24	-	-	-	51,352.60	-	-	-	55,608.37
XIII	Earning Per Share (EPS) (of Re. 1/- each) (not annualised)												
	Basic Earnings Per Share (in Rupees)	14.08	7.85	9.60	35.95	8.26	5.37	11.81	28.49	7.90	5.35	11.53	27.44
	Diluted Earnings Per Share (in Rupees)	14.08	7.85	9.60	35.95	8.26	5.37	11.81	28.49	7.90	5.35	11.53	27.44

Notes:

1. The above results were reviewed by the Audit Committee at its meeting held on 9 August, 2018 and approved at the meeting of the Board of Directors held on 10 August, 2018.
2. The results for the quarter ended 30 June, 2018 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
3. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July, 2016. The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the Regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
4. Effective 1 April, 2018, the Company adopted IND AS 115 or IFRS 15 " Revenue from Contracts with customers", as the case may be using the modified restrospective transition method. There was no material effect on the financial results on adoption of IND AS 115 or IFRS 15, as the case may be.
5. The list of subsidiaries as of 30 June, 2018 is provided in Annexure A.
6. The Company operates in one reportable business segment i.e., Pharmaceuticals.
7. As at 30 June, 2018, pursuant to Employee Stock Options Scheme 2016, 5,56,914 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
8. Diluted EPS has been computed considering the effect of conversion of ESOPs.
9. Post implementation of Goods and Service Tax ('GST') with effect from 1 July, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in GST. Revenue from operations for year ended 31 March, 2018 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for quarter ended 30 June, 2018 is not comparable with previous periods presented.
10. The figures for the quarter ended 31 March 2018 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the figures for the third quarter of the relevant financial year.
11. Previous period's figures have been re-grouped/re-classified wherever necessary.

Annexure A

List of entities included in the consolidated financial results for the quarter ended 30 June 2018

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. **2.**Glenmark Pharmaceuticals Europe Ltd., U.K. **3.**Glenmark Pharmaceuticals S.R.O. **4.**Glenmark Pharmaceuticals SK, S.R.O. **5.**Glenmark Pharmaceuticals S. A. **6.**Glenmark Holding S.A. **7.**Glenmark Pharmaceuticals S.R.L **8.**Glenmark Pharmaceuticals SP z.o.o. **9.**Glenmark Pharmaceuticals Inc. (formerly Glenmark Generics Inc.) **10.**Glenmark Therapeutics Inc. **11.**Glenmark Farmaceutica Ltda **12.**Glenmark Generics S.A **13.**Glenmark Pharmaceuticals Mexico, S.A. DE C.V. **14.**Glenmark Pharmaceuticals Peru SAC **15.**Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) **16.**Glenmark Uruguay S.A. **17.**Glenmark Pharmaceuticals Venezuela, C.A **18.**Glenmark Dominicana SRL **19.**Glenmark Pharmaceuticals Egypt S.A.E. **20.**Glenmark Pharmaceuticals FZE **21.**Glenmark Impex L.L.C **22.**Glenmark Philippines Inc. **23.**Glenmark Pharmaceuticals (Nigeria) Ltd. **24.**Glenmark Pharmaceuticals Malaysia Sdn Bhd **25.**Glenmark Pharmaceuticals (Australia) Pty Ltd **26.**Glenmark South Africa (pty) Ltd **27.**Glenmark Pharmaceuticals South Africa (pty) Ltd **28.**Glenmark Pharmaceuticals (Thailand) Co. Ltd **29.**Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) **30.**Glenmark Arzneimittel Gmbh **31.**Glenmark Pharmaceuticals Canada Inc. (formerly Glenmark Generics Canada Inc.) **32.**Glenmark Pharmaceuticals Kenya Ltd **33.**Glenmark Therapeutics AG **34.**Viso Farmaceutica S.L., Spain **35.**Glenmark Specialty SA **36.**Glenmark Pharmaceuticals Distribution s.r.o. **37.**Glenmark Pharmaceuticals Nordic AB **38.**Glenmark Ukraine LLC **39.**Glenmark-Pharmaceuticals Ecuador S.A. **40.**Glenmark Pharmaceuticals Singapore Pte. Ltd.

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director

Mumbai, August 10, 2018